Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy

Correction: J Exp Clin Cancer Res 43, 251 (2024)

https://doi.org/10.1186/s13046-024-03165-x

Following publication of the original article [1], the authors found an error in the affiliation of the 5th author, Zahid Rafiq. He was mistakenly assign to Affiliation 1. The details are given below:

Incorrect affiliation:

¹ Department of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.

Correct affiliation:

² Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

This correction does not affect the overall result or conclusion of the article. The original article [1] has been corrected.

1. He K, Puebla-Osorio N, Barsoumian HB, et al. Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy. J Exp Clin Cancer Res. 2024;43:251. https://doi.org/10.1186/s13046-024-03165-x.

   Article CAS PubMed PubMed Central Google Scholar

Download references

Authors and Affiliations

1. Department of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong, China

   Kewen He

2. Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

   Kewen He, Nahum Puebla-Osorio, Hampartsoum B. Barsoumian, Duygu Sezen, Zahid Rafq, Thomas S. Riad, Yun Hu, Ailing Huang, Tifany A. Voss, Claudia S. Kettlun Leyton, Lily Jae Schuda, Ethan Hsu, Maria-Angelica Cortez & James W. Welsh

3. Department of Radiation Oncology, Koç University School of Medicine, Istanbul, Turkey

   Duygu Sezen

4. Mural Oncology PLC, Waltham, MA, USA

   Joshua Heiber

Authors

1. Kewen HeView author publications

   You can also search for this author in PubMed Google Scholar

2. Nahum Puebla-OsorioView author publications

   You can also search for this author in PubMed Google Scholar

3. Hampartsoum B. BarsoumianView author publications

   You can also search for this author in PubMed Google Scholar

4. Duygu SezenView author publications

   You can also search for this author in PubMed Google Scholar

5. Zahid RafqView author publications

   You can also search for this author in PubMed Google Scholar

6. Thomas S. RiadView author publications

   You can also search for this author in PubMed Google Scholar

7. Yun HuView author publications

   You can also search for this author in PubMed Google Scholar

8. Ailing HuangView author publications

   You can also search for this author in PubMed Google Scholar

9. Tifany A. VossView author publications

   You can also search for this author in PubMed Google Scholar

10. Claudia S. Kettlun LeytonView author publications

    You can also search for this author in PubMed Google Scholar

11. Lily Jae SchudaView author publications

    You can also search for this author in PubMed Google Scholar

12. Ethan HsuView author publications

    You can also search for this author in PubMed Google Scholar

13. Joshua HeiberView author publications

    You can also search for this author in PubMed Google Scholar

14. Maria-Angelica CortezView author publications

    You can also search for this author in PubMed Google Scholar

15. James W. WelshView author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Kewen He or James W. Welsh.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at https://doi.org/10.1186/s13046-024-03165-x.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

Cite this article

He, K., Puebla-Osorio, N., Barsoumian, H.B. et al. Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy. J Exp Clin Cancer Res 43, 256 (2024). https://doi.org/10.1186/s13046-024-03183-9

Download citation

• Published: 10 September 2024

• DOI: https://doi.org/10.1186/s13046-024-03183-9

Share this article

Anyone you share the following link with will be able to read this content:

Get shareable link

Sorry, a shareable link is not currently available for this article.

Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative